Immunogenic combination compositions and uses thereof
This invention generally relates to immunogenic compositions that comprise an RNA component and a polypeptide component. Immunogenic compositions that deliver antigens in two different forms—a first antigen from a pathogen, in RNA-coded form; and a second antigen from a different pathogen, in polypeptide form—are effective in inducing immune response to both pathogens.
1. An immunogenic composition comprising:
(i) a first polypeptide antigen derived from the group consisting of a viral pathogen and a bacterial pathogen, and
(ii) a self-replicating RNA molecule encapsulated within a liposome, wherein said self-replicating RNA molecule cannot induce production of infectious viral particles, encodes a second polypeptide antigen from a viral pathogen, and can promote T cell-mediated immunity as well as humoral immunity to both first and second antigens,
wherein said first and second antigens are antigens from different pathogens,
wherein the self-replicating RNA molecule is not encapsulated in a virus-like particle; and
wherein the liposome encapsulating the self-replicating RNA molecule does not include capsid protein or envelope glycoproteins.
2. The immunogenic composition of claim 1 , wherein said second polypeptide antigen is a Cytomegalovirus (CMV) antigen.
3. The immunogenic composition of claim 1 , wherein said first polypeptide antigen is in the form of a virus-like particle (VLP).
4. The immunogenic composition of claim 1 , wherein said first polypeptide antigen is a soluble polypeptide and said second polypeptide antigen is a soluble or membrane anchored polypeptide.
5. The immunogenic composition of claim 1 , wherein the self-replicating RNA is an alphavirus-derived RNA replicon.
6. The immunogenic composition of claim 1 , wherein the self-replicating RNA molecule comprises one or more modified nucleotides.
7. The immunogenic composition of claim 1 , wherein the first polypeptide antigen and second polypeptide antigen are both viral antigens.
8. The immunogenic composition of claim 7 , wherein one viral antigen is an antigen from CMV.
9. An immunogenic composition comprising:
(i) a first viral polypeptide antigen, and
(ii) a self-replicating RNA molecule encapsulated within a liposome, wherein said self-replicating RNA molecule cannot induce production of infectious viral particles, encodes a second viral polypeptide antigen from a viral pathogen, and can promote T cell-mediated immunity as well as humoral immunity to both first and second antigens,
wherein said first and second antigens are antigens from different viral pathogens,
wherein one viral antigen is a Parvovirus antigen.
10. The immunogenic composition of claim 9 , wherein the Parvovirus antigen comprises an amino acid sequence encoded by SEQ ID NO: 25 or 26.
11. The immunogenic composition of claim 1 , further comprising an adjuvant.
12. An immunogenic composition comprising: (i) a Parvovirus polypeptide antigen, and (ii) a self-replicating RNA molecule that encodes a CMV polypeptide antigen.
13. A method for inducing an immune response in a subject comprising administering to a subject in need thereof a therapeutically effective amount of a composition according to claim 1 .